201
|
Castellanos M, Desai N, Foss C, Balducci J, Hibner M. Removal of the Retained Cervical Stump for the Treatment of Chronic Pelvic Pain. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
202
|
Dassel M, Desai N, Hibner M. Predictive Value of Single Versus Multiple Peritoneal Biopsies for the Diagnosis of Endometriosis in a Benign Appearing Pelvis on Laparoscopy in the Setting of Chronic Pelvic Pain. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
203
|
Desai N, AbdelHafez F, Goldberg J, Austin C. Clinical outcomes of blastocyst transfer using a single culture medium. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
204
|
Desai N, Khanna P, AbdelHafez F, Goldberg J. Secretion of soluble HLA-G by embryos vitrified on day 3 and outcome in subsequent frozen embryo transfer cycles. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
205
|
Flyckt R, Goldberg J, Desai N. Examination of blastocyst transfer cycles, implantation failures, and pregnancy potential in a subsequent frozen embryo transfer. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
206
|
Desai N, AbdelHafez F, Goldberg J, Austin C. Observations on different patterns of human embryonic compaction on day 4 and subsequent embryonic development to blastocyst. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
207
|
George SMC, Desai N, Shepherd J, Harland CC. A distinctive flexural eruption implicating Pseudomonas aeruginosa. Clin Exp Dermatol 2011; 37:184-6. [DOI: 10.1111/j.1365-2230.2011.04130.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
208
|
Desai N, Schillinger J, Bratu S, Eramo A, Bowers C, Agrawal A. P1-S1.18 Investigating a cluster of neonatal herpes at a single institution. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050108.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
209
|
Nathan DP, Lai E, Boonn W, Wang GJ, Desai N, Woo EY, Fairman RM, Jackson BM. Natural History of Penetrating Atherosclerotic Ulcers. J Vasc Surg 2011. [DOI: 10.1016/j.jvs.2010.11.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
210
|
O'Leary T, Heindryckx B, Lierman S, De Sutter P, Shlush K, Fainaru O, Grosman G, Faraji G, Michaeli M, Hallak M, Ellenbogen A, Zambelli F, Magli MC, Stanghellini I, Ferraretti AP, Ventura C, Gianaroli L, Mas A, Cervello I, Gil-Sanchis C, Peris-Pardo L, Faus A, Ferro J, Pellicer A, Simon C, Kobayashi M, Kurotaki Y, Takeuchi T, Yoshida A, Behjati R, Kawai K, Kano J, Akhondi MA, Akaza H, Noguchi M, Desai N, Tsulaia T, Xu J, Anand R, Goldberg J, Falcone T, Eguizabal C, Montserrat N, Vassena R, Barragan M, Garreta E, Garcia-Quevedo L, Vidal F, Giorgetti A, Veiga A, Ispizua-Belmonte JC, Carrasco B, Vassena R, Boada M, Coroleu B, Izpisua JC, Veiga A, Chikhovskaya JV, Repping S, van Pelt AMM, Namm A, Arend A, Aunapuu M, Duggal G, Heindryckx B, O'Leary T, Lierman S, Deforce D, Chuva de Sousa Lopes S, De Sutter P, Koruji M, Janan A, Azizi H, Mirzapour T, Shahverdi A, Baharvand H, Medrano JV, Nguyen HN, Ramathal C, Simon C, Reijo Pera RA, Salit M, Sabry D, Azmy O, Al-Inany H, Montico F, Hetzl AC, Billis A, Favaro WJ, Cagnon VHA, Ben - Yosef D, Amit A, Malcov M, Frumkin T, Eldar I, Mei Raz N, Shwartz T, Azem F, Altarescu G, Beeri B, Varshaver I, Eldar-Geva T, Epsztejn-Litman S, Levy-Lahad E, Eiges R, Sergeev SA, Khramova YV, Kosheleva NV, Saburina IN, Semenova ML. POSTER VIEWING SESSION - STEM CELLS. Hum Reprod 2011. [DOI: 10.1093/humrep/26.s1.93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
211
|
Volk LD, Wilber A, Trieu V, Desai N, Ran S. Abstract P1-03-09: Combination of nab-Paclitaxel and Bevacizumab Inhibited Tumor Growth and Metastasis of New Inflammatory Breast Cancer Models. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-03-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is a highly lethal form of breast cancer which is characterized by skin redness, irritation, swelling, pain, as well as extensive lymph nodes (LN) and hematogenous metastasis. Animal models of IBC are highly desirable for studying its pathology and for designing effective therapies. In this study, we established two new luciferase-and fluorescently-labeled IBC models and tested the efficacy of the novel drug combination nab-paclitaxel and bevacizumab. Methods: Inflammatory SUM149 breast cancer cells were stably transfected with Red Fluorescent Protein (RFP) and Renilla luciferase to establish SUM149-RR, or infected with lentivirus encoding Green Fluorescent Protein (GFP) and Firefly luciferase to establish SUM149- GL. The new cell lines were characterized both in vitro and in vivo. Immunodeficient mice bearing SUM149-RR tumors of 150mm3 in size were treated with saline (control), bevacizumab (4 mg/kg, i.p., twice a week, for 10 weeks), nab-paclitaxel (10 mg/kg, i.v., qdx5), or the combination. Metastasis was analyzed by measuring luciferase activity in the lymph nodes (LN) and lungs.
Results: Luciferase measurements and in vivo imaging showed that both SUM149-RR and-GL clones were highly metastatic to LN, lungs, liver, brain, and spleen. SUM149-RR tumors in control mice displayed ulcerations, edema and redness similar to the clinical disease, while tumors in mice treated with bevacizumab or combination therapy showed no signs of inflammation. Bevacizumab alone decreased tumor growth at later but not early stages of tumor growth, whereas nab-paclitaxel alone inhibited tumor growth by 73%. Combination therapy increased inhibition to 96%, and resulted in 22% (2/9) complete responses. Histologically, tumors from bevacizumab treated groups were more morphologically intact with reduced vascular abnormalities than tumors from control or nab-paclitaxel treated mice. LN and lung metastasis was significantly reduced in all treated groups as compared with control.
Conclusions: The SUM149-RR and SUM149-GL lines are new double-tagged models of human IBC that allow organ visualization and accurate quantification of metastasis. These models can be used to study the biology and treatment of IBC. Combination of nab-paclitaxel with bevacizumab was highly effective against SUM149-RR, suggesting the potential usefulness of this regimen for treatment of IBC patients.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-03-09.
Collapse
|
212
|
Ran S, Trieu V, Volk LD, Wilber A, Desai N. Abstract P1-03-11: Combination of nab-Paclitaxel and Bevacizumab Inhibited Tumor Growth and Metastasis of a New Triple Negative Breast Cancer Model. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-03-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancers are highly aggressive and resistant to chemotherapy. In this study, we established a new model of triple-negative breast cancer and used it to test the novel combination of nab-paclitaxel with anti-VEGF antibody bevacizumab, which has been effective in treating other metastatic cancer types. Methods: The triple-negative HCC1806 beast cancer cells were stably transfected with dual reporters Red Fluorescent Protein (RFP) and Renilla luciferase to establish the new HCC1806-RR model. Immunodeficient mice bearing orthotopic HCC1806-RR tumors of 150mm3 in size were treated with saline (control), bevacizumab (4 mg/kg. i.p., twice a week, for 10 weeks), nab-paclitaxel (10 mg/kg, i.v., qdx5), or with combination of nab-paclitaxel and bevacizumab. Metastasis was analyzed by measuring luciferase activity in the lymph nodes (LN) and lungs. Results: The HCC1806-RR cells had identical morphology, proliferation rates and sensitivity to nab-paclitaxel as the parental HCC1806 cell line. HCC1806-RR tumors primarily metastasized to LN, with lung being a secondary metastatic site. Combination therapy of nab-paclitaxel and bevacizumab inhibited tumor growth by 100%, as compared to 0% for bevacizumab (P < 0.001) and 90% for nab-paclitaxel (P = 0.024). Importantly, only combination therapy reduced incidence of LN and lung metastases by 50% (P = 0.007) and 87% (P = 0.001). Overall, 50% of the mice in the combination therapy group (n = 10) had complete regressions of both primary tumors and metastases at both regional and distant sites. Conclusions : The HCC1806-RR is a new triple-negative breast model with dual reporters to allow for quantitative assessment of metastatic spread. This model can be used to study the biology and treatment of triple-negative breast cancer. Combination of nab-paclitaxel with bevacizumab was highly effective against HCC 1806-RR tumors, suggesting that this regimen could provide clinical benefits to patients with triple-negative breast cancers.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-03-11.
Collapse
|
213
|
Tao C, Ci S, D'Cruz O, Piacente M, Han H, Weingarten P, Wang Q, Mushtaq G, Trieu V, Desai N. 202 Antitumor efficacy of novel hedgehog inhibitors. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71907-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
214
|
Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13. [PMID: 21034824 DOI: 10.1016/j.vaccine.2010.10.037] [Citation(s) in RCA: 157] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2010] [Revised: 09/17/2010] [Accepted: 10/13/2010] [Indexed: 10/18/2022]
Abstract
Ebola virus causes irregular outbreaks of severe hemorrhagic fever in equatorial Africa. Case mortality remains high; there is no effective treatment and outbreaks are sporadic and unpredictable. Studies of Ebola virus vaccine platforms in non-human primates have established that the induction of protective immunity is possible and safety and human immunogenicity has been demonstrated in a previous Phase I clinical trial of a 1st generation Ebola DNA vaccine. We now report the safety and immunogenicity of a recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, in a randomized, placebo-controlled, double-blinded, dose escalation, Phase I human study. Thirty-one healthy adults received vaccine at 2×10(9) (n=12), or 2×10(10) (n=11) viral particles or placebo (n=8) as an intramuscular injection. Antibody responses were assessed by ELISA and neutralizing assays; and T cell responses were assessed by ELISpot and intracellular cytokine staining assays. This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses.
Collapse
|
215
|
Desai N, AbdelHafez F, Cynthia A, Goldberg J, Falcone T, Goldfarb J. Update on clinical outcomes and live births with human embryo vitrification at the 6-8 cell stage: embryonic activation after warming and impact on clinical pregnancy and implantation. Fertil Steril 2010. [DOI: 10.1016/j.fertnstert.2010.07.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
216
|
Desai N, Falcone T, Goldberg J, Austin C, Goldfarb J. What is the optimal stage for embryo vitrification-a comparison of embryo survival and clinical outcomes with day 3 cleavage versus blastocyst stage vitrification. Fertil Steril 2010. [DOI: 10.1016/j.fertnstert.2010.07.454] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
217
|
Desai N, Xu J, Tsulaia T, Szeptycki J, Falcone T, Goldfarb J. Vitrification of mouse embryo derived ICM cells: a tool for preserving embryonic stem cell potential? Fertil Steril 2010. [DOI: 10.1016/j.fertnstert.2010.07.930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
218
|
Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer R. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) 2010; 49:2024-36. [DOI: 10.1093/rheumatology/keq208] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
219
|
Desai N, Natkunarajah J, Chong H, Millington GMW. Symmetrical papulonodular eruption of the elbows. Clin Exp Dermatol 2010; 35:e199-200. [PMID: 20518915 DOI: 10.1111/j.1365-2230.2009.03744.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
220
|
Blackwell KL, Hamilton EP, Rocha G, Gainey M, Trieu VN, Motamed K, Pramanik P, Hwang L, Treece T, Desai N. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21040] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
221
|
Yardley DA, Daniel BR, Inhorn RC, Vazquez ER, Trieu VN, Motamed K, Hwang L, Rugo HS, Desai N. SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel ( nab-P) in locally advanced breast cancer (LABC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10574] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
222
|
Desai N, Piacente M, Liu X, D'Cruz O, Hwang L, Lin X, Ran S, Markovic S, Motamed K, Trieu VN. Effect of plasma SPARC on outcome in cancer models. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
223
|
Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, Chadaram V, Welch R, Trieu VN, Blackwell KL. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
224
|
Abu-Khalaf MM, Gettinger SN, Trieu VN, Deshpande HA, DiGiovanna M, Azodi M, Desai N, Kelly WK, Schwartz PE, Harris L. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2534] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
225
|
Markovic S, Suman V, Trieu VN, Liu X, Yeh W, Hwang L, Treece T, Motamed K, Pramanik P, Desai N. Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|